10-K: Arvinas 10-K: Vepdegestrant NDA Accepted, Pipeline Advances

Arvinas, a clinical-stage biotechnology company, reports its 2025 annual results, highlighting the FDA's acceptance of its vepdegestrant NDA and progress across its PROTAC degrader pipeline, alongside strategic workforce reductions and a shift in vepdegestrant commercialization strategy.

Summary

• Net loss for the year ended December 31, 2025, was $80.8 million, a significant improvement from $198.9 million in 2024 and $367.3 million in 2023.
• Revenue for 2025 totaled $262.6 million, a slight decrease from $263.4 million in 2024, primarily due to changes in collaboration agreements.
• Research and development expenses decreased to $285.2 million in 2025 from $348.2 million in 2024, driven by lower compensation and external expenses.
• General and administrative expenses decreased to $95.9 million in 2025 from $165.4 million in 2024, partly due to a $43.4 million loss on lease termination in 2024.
• Cash, cash equivalents, and marketable securities totaled $685.4 million as of December 31, 2025, projected to fund planned operating expenses and capital expenditure requirements into the second half of 2028.
• The FDA accepted the New Drug Application (NDA) for vepdegestrant for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, assigning a PDUFA action date of June 5, 2026.
• Arvinas and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.
• The company completed dose escalation for once-weekly administration of ARV-806 in its Phase 1 clinical trial ahead of schedule due to faster-than-anticipated enrollment.
• A first-in-human Phase 1 clinical trial for ARV-027 in healthy volunteers was initiated in the first quarter of 2026.
• The company plans to initiate a Phase 1 clinical trial for ARV-6723 in patients with advanced solid tumors in mid-2026.
• Enrollment in the multiple dose cohort of the ARV-102 Phase 1 clinical trial in Parkinson's disease patients was completed in the fourth quarter of 2025.
• The company repurchased 10,009,758 shares of its common stock for an aggregate purchase price of $91.0 million in 2025, and the program has been suspended as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by significant clinical and regulatory progress for vepdegestrant and other pipeline candidates, coupled with improved financial performance and extended cash runway. However, the strategic shift in vepdegestrant commercialization and ongoing losses temper the overall sentiment.

Positives

• Net loss significantly decreased to $80.8 million in 2025 from $198.9 million in 2024, indicating improved financial efficiency.
• The FDA accepted the New Drug Application (NDA) for vepdegestrant, a major regulatory milestone for the company and the PROTAC platform, with a PDUFA date of June 5, 2026.
• Positive topline results from the Phase 3 VERITAC-2 clinical trial for vepdegestrant in ESR1m patients demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (HR=0.57, p<0.001) compared to fulvestrant.
• Vepdegestrant showed improved clinical benefit rate (42.1% vs 20.2%) and objective response rate (18.6% vs 4.0%) in ESR1m patients compared to fulvestrant.
• The safety profile of vepdegestrant in VERITAC-2 was generally well tolerated and consistent with previous studies, with mostly low-grade treatment-emergent adverse events.
• Patient Reported Outcomes (PRO) data from VERITAC-2 indicated vepdegestrant reduced the risk of deterioration in overall health status, pain severity, and functioning compared to fulvestrant.
• ARV-102 Phase 1 clinical data in healthy volunteers and Parkinson's disease patients demonstrated substantial LRRK2 reduction in cerebrospinal fluid (CSF), brain penetration, and a promising safety/tolerability profile.
• Dose escalation for the ARV-806 Phase 1 clinical trial was completed ahead of schedule due to faster-than-anticipated patient enrollment.
• Preclinical data for ARV-806 showed high potency and selectivity, with robust antitumor activity, demonstrating more than 25-fold greater potency than clinical-stage KRAS G12D inhibitors and more than 40-fold greater potency than the leading clinical-stage KRAS G12D degrader.
• ARV-393 preclinical data demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard of care chemotherapy and biologics in aggressive diffuse large B-cell lymphoma models.
• Cash, cash equivalents, and marketable securities of $685.4 million as of December 31, 2025, are expected to fund operations into the second half of 2028, providing a solid financial runway.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $1,612.4 million as of December 31, 2025, and has never generated revenue from product sales.
• The decision to jointly select a third party for vepdegestrant commercialization and future development indicates a departure from previous plans to build internal commercial infrastructure, potentially limiting direct control over future revenue streams.
• Workforce reductions of approximately 33% in April 2025 and an additional 15% in September 2025, primarily affecting vepdegestrant commercialization roles, may disrupt operations and impact employee morale and retention.
• The VERITAC-2 trial did not reach statistical significance in improvement in progression-free survival (PFS) in the intent-to-treat (ITT) population (HR=0.83, p=0.07).
• Two planned Phase 3 combination trials for vepdegestrant were removed from the agreed-upon joint development plan with Pfizer.
• The share repurchase program was suspended as of December 31, 2025, with no further plans to repurchase additional shares, potentially removing a source of shareholder value return.
• Other income decreased by $13.9 million in 2025, primarily due to lower interest income from marketable securities and money market accounts.

Risks

• The company has incurred significant losses since inception and expects to continue incurring expenses and operating losses for at least the next several years, and may never achieve or maintain profitability.
• Substantial additional funding will be needed to continue operations; inability to raise capital when needed may require delaying, limiting, reducing, or terminating research, product development programs, or future commercialization efforts.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• The PROTAC technology platform is unproven, making it difficult to predict the time, cost of development, and likelihood of successfully developing any products.
• No product candidates have been approved for commercialization; significant delays in commercialization would materially harm the business.
• Drug development is a lengthy and expensive process with an uncertain outcome, potentially leading to unexpected costs or delays.
• Positive data from preclinical or early clinical studies are not necessarily predictive of results in later clinical studies.
• Limited resources may be expended on a particular product candidate or indication, leading to a failure to capitalize on more profitable opportunities.
• Reliance on third parties, including Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs)/Contract Development and Manufacturing Organizations (CDMOs), to conduct clinical trials and manufacturing, which may not perform satisfactorily.
• Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact business and operating results (e.g., tariffs, supply chain disruptions).
• Even if any product candidate receives marketing approval, it may fail to achieve the necessary degree of market acceptance by physicians, patients, and third-party payors for commercial success.
• Approved products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Inability to obtain and maintain patent protection for technology and products, or if the scope of protection is not sufficiently broad, competitors could develop and commercialize similar products.
• The regulatory approval process is lengthy, time-consuming, and inherently unpredictable; failure to obtain marketing approval would substantially harm the business.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities or inhibit the ability to collect and process data globally.
• Future success depends on the ability to retain key employees, consultants, and advisors, and to attract, train, retain, and motivate qualified personnel.
• Internal computer systems and those of collaborators are vulnerable to cyber attacks, cyber intrusions, and security breaches, which could disrupt business operations, result in loss of confidential information, and damage clinical trial integrity.
• The price of common stock is volatile and may fluctuate substantially, potentially resulting in the loss of all or part of stockholders' investment.
• Subject to anti-corruption laws, export control laws, customs laws, sanctions laws, and other laws governing operations, with potential for civil or criminal penalties for non-compliance.
• Social media platforms and AI-based platforms present new risks and challenges, including potential for unauthorized information release, reputational harm, or unintended biases.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its preclinical and clinical development programs. Cash, cash equivalents, and marketable securities of $685.4 million as of December 31, 2025, are expected to fund operations into the second half of 2028. The company plans to present further clinical data for ARV-102 and ARV-393 in 2026, initiate Phase 1 trials for ARV-027 and ARV-6723 in 2026, and potentially a registrational trial for ARV-102 in PSP in late 2026. The company and Pfizer will jointly select a third party for vepdegestrant commercialization and potential future development.

Management Comments

• "We believe favorable clinical trial results in our ongoing oncology and neurology programs would further validate our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins."
• "We believe our LRRK2 degraders are particularly well positioned to be evaluated in neurodegenerative diseases where there are currently no disease modifying therapies available, including Parkinson's disease and progressive supranuclear palsy."
• "We believe the data from our preclinical studies of ARV-102 further support the potential of PROTAC-induced LRRK2 degradation as a treatment for patients with neurodegenerative disease."
• "We believe ARV-806 has the potential to address high unmet need in solid tumors, such as pancreatic, colorectal and non-small cell lung cancer ('NSCLC'), with KRAS G12D mutation."
• "We believe ARV-806 has the potential to be developed as a monotherapy and in combination with chemotherapy in pancreatic ductal adenocarcinoma and in combination with standard of care ('SOC') treatments in colorectal and non-small cell lung cancer."
• "We believe preclinical data for ARV-806 supports intermittent clinical dosing."
• "We believe that PROTAC-mediated degradation has the potential to address the historically undruggable nature of the B-cell lymphoma 6 protein ('BCL6') and that ARV-393 PROTAC-mediated degradation of BCL6 may provide an important novel therapeutic option for patients with non-Hodgkin lymphoma."
• "We believe that ARV-393 can be an attractive combination partner for development of novel therapies for lymphoma, including chemo-free combination regimens and/or all oral treatment options."
• "We believe the totality of our preclinical data for ARV-393 provides a compelling rationale to evaluate ARV-393 in combination with bi-specifics, oral pathway inhibitors, and potentially other standards of care, in the larger diffuse large B-cell lymphoma indication."
• "We believe that, based on these strong data from VERITAC-2, vepdegestrant has the potential to be a best-in-class monotherapy treatment for advanced/metastatic breast cancer patients in the second-line ESR1m setting."
• "While we continue to believe that vepdegestrant has the potential to be a best-in-class monotherapy treatment for advanced/metastatic breast cancer patients in the second-line ESR1m setting, given our and Pfizer's decision to remove the two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan as noted above, we determined that it is no longer viable for us to build out our commercial infrastructure as we had previously planned."
• "We believe these preclinical results support future investigation of ARV-6723 alone or in combination with other agents in patients with highor low-immunogenic tumors."
• "We believe selectively targeting KRAS for removal may have benefits to tolerability compared with a pan-RAS approach."
• "We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into the second half of 2028, which will enable us to execute on multiple data readouts across our programs."

Industry Context

StockSavvy.ai notes that Arvinas is pioneering PROTAC protein degradation, a novel therapeutic modality aiming to address historically undruggable targets, positioning it against traditional small molecule inhibitors, antibodies, and gene-based medicines. The company operates in highly competitive oncology and neurology sectors, facing established pharmaceutical giants and other biotech firms also investing in protein degradation. The strategic shift in vepdegestrant's commercialization strategy reflects the challenges of building out a commercial infrastructure in a competitive market, potentially indicating a focus on its core R&D and platform value.

Comparison to Industry Standards

• ARV-806 demonstrated in vitro potency more than 25 times greater than clinical stage KRAS G12D "ON" and "OFF" inhibitors and more than 40 times greater than the leading KRAS G12D clinical-stage degrader.
• Vepdegestrant showed a 43% reduction in the risk of disease progression or death (Hazard Ratio = 0.57) compared to fulvestrant in ESR1m patients, with a median Progression-Free Survival (PFS) of 5.0 months versus 2.1 months for fulvestrant, a current standard of care Selective Estrogen Receptor Degrader (SERD).
• ARV-6723, as a single agent, demonstrated anti-tumor efficacy superior to anti-PD1 or a clinical HPK1 inhibitor and combined with anti-PD1 to further enhance response.
• A tool pan-KRAS PROTAC demonstrated robust single-agent activity and superior combination efficacy with immune checkpoint blockade compared with a pan-RAS ON inhibitor (seven complete responses compared with two complete responses).
• The company's PROTAC platform is presented as having distinct advantages over existing therapies, including addressing historically undruggable proteins, potential for oral dosing and systemic distribution, catalytic and durable effects, and compatibility with established small-molecule manufacturing processes.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or legal proceedings.

Related Party Transactions

• The company has an Amended and Restated License Agreement with Yale University, from which it exclusively licenses foundational intellectual property rights for its PROTAC targeted protein degradation technology. This agreement involves an upfront payment, annual license maintenance fees, and success-based milestones.
• The company co-owns six patent families with Yale University describing composition of matter claims of PROTAC targeted protein degrader compounds.
• The company co-owns four patent families with Genentech directed to PROTAC targeted protein degrader compounds addressing a specific protein.

Stakeholder Impact

• Shareholders: Potential for increased value from pipeline advancements and regulatory approvals, but also risk of dilution from future capital raises and stock price volatility. The share repurchase program was completed in 2025.
• Employees: Significant workforce reductions (33% in April 2025, additional 15% in September 2025) may impact morale and retention, but the company emphasizes creating an equitable and inclusive environment and providing competitive compensation.
• Customers/Patients: Potential for new therapeutic options for debilitating and life-threatening diseases, particularly in oncology and neurodegenerative diseases, with vepdegestrant NDA acceptance being a key step towards market availability.
• Partners (Pfizer, Novartis, Genentech): Ongoing collaborations and licensing agreements are critical for development and commercialization, with the vepdegestrant commercialization strategy shifting to a third-party partner, potentially altering future revenue sharing and development dynamics.
• Creditors: Financial stability is supported by $685.4 million in cash and equivalents, projected to fund operations into the second half of 2028, indicating a manageable liquidity position in the near to medium term.

Next Steps

• Present data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in Parkinson's disease patients in Q1 2026 at 2026 AD/PD.
• Initiate a Phase 1b clinical trial of ARV-102 in patients with Progressive Supranuclear Palsy (PSP) in the first half of 2026, pending regulatory feedback.
• Potentially initiate a registrational trial of ARV-102 in PSP in late 2026, pending regulatory feedback.
• Continue enrollment in the ARV-806 Phase 1 clinical trial and anticipate sharing initial clinical data in 2026.
• Initiate enrollment of a glofitamab combination cohort in patients with Diffuse Large B-cell Lymphoma (DLBCL) in the ongoing Phase 1 clinical trial of ARV-393 in the first half of 2026.
• Share updated clinical data from the ongoing Phase 1 clinical trial of ARV-393 in patients with relapsed/refractory Non-Hodgkin Lymphoma (NHL) at a medical congress in the second half of 2026.
• Initiate a first-in-human Phase 1 clinical trial for ARV-027 in healthy volunteers in Q1 2026.
• Continue market preparations for vepdegestrant in advance of the PDUFA date of June 5, 2026.
• Jointly select a third party with Pfizer for the commercialization and potential future development of vepdegestrant.
• Present preclinical data evaluating antitumor and unique immunomodulatory activity of ARV-6723 in immuno-oncology-resistant models compared to Standard of Care (SOC) checkpoint inhibition in the first half of 2026.
• Initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors in mid-2026, pending regulatory feedback.
• Present preclinical data evaluating the activity and selectivity of a novel pan-KRAS degrader in multiple KRAS mutants and differentiation over RAS (ON) or pan-KRAS inhibitors in Q1 2026 at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics.
• Present preclinical data evaluating the efficacy of a novel pan-KRAS degrader in a KRAS syngeneic model, as well as associated immune microenvironment changes in the first half of 2026.

Key Dates

Recommendation

The company has made significant progress with its pipeline, particularly the vepdegestrant NDA acceptance and positive Phase 3 data, which are strong indicators of potential future value. The extended cash runway provides stability. However, the shift in vepdegestrant's commercialization strategy and ongoing net losses introduce uncertainty regarding the path to profitability and the ultimate commercial success of its lead candidate. The stock price is likely to remain volatile as the company navigates these strategic changes and awaits further clinical and regulatory milestones. A 'hold' recommendation is appropriate given the balance of promising pipeline developments and strategic uncertainties.

Keywords

Biotechnology, PROTAC, Protein Degradation, Oncology, Neurology, Breast Cancer, Parkinson's Disease, Non-Hodgkin Lymphoma, Spinal Bulbar Muscular Atrophy, KRAS G12D, LRRK2, BCL6, ER, Vepdegestrant, ARV-102, ARV-806, ARV-393, ARV-027, ARV-6723, Clinical Trials, FDA, NDA, PDUFA, Pharmaceutical, Drug Development, Targeted Therapy